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Abstract: 
The aim of our present work was to evaluate the applicability of the Quality by Design (QbD) 
methodology in the development and optimalization of nanostructured lipid carriers 
containing salicyclic acid (NLC SA). Within the Quality by Design methology, special 
emphasis is layed on the adaptation of the initial risk assessment step in order to properly 
identify the critical material attributes and critical process parameters in formulation 
development. 
NLC SA products were formulated by the ultrasonication method using Compritol 888 ATO 
as solid lipid, Miglyol 812 as liquid lipid and Cremophor RH 60
®
 as surfactant. LeanQbD 
Software and StatSoft. Inc. Statistica for Windows 11 were employed to indentify the risks.  
Three highly critical quality attributes (CQAs) for NLC SA were identified, namely particle 
size, particle size distribution and aggregation.  Five attributes of medium influence were 
identified, including dissolution rate, dissolution efficiency, pH, lipid solubility of the active 
pharmaceutical ingredient (API) and entrapment efficiency.  
Three critical material attributes (CMA) and critical process parameters (CPP) were 
identified: surfactant concentration, solid lipid/liquid lipid ratio and ultrasonication time. The 
CMAs and CPPs are considered as independent variables and the CQAs are defined as 
dependent variables. The 2
3
 factorial design was used to evaluate the role of the independent 
and dependent variables. Based on our experiments, an optimal formulation can be obtained 
when the surfactant concentration is set to 5%, the solid lipid/liquid lipid ratio is 7:3 and 
ultrasonication time is 20 minutes. The optimal NLC SA showed narrow size distribution 
(0.857 ± 0.014 ) with a mean  particle size of 114 ± 2.64 nm. The NLC SA product showed a 
significantly higher in vitro drug release compared to the micro-particle reference preparation 
containing salicylic acid (MP SA).  
 
Keywords: NLC, Quality by Design, risk assessment, critical quality attributes, 2
3
 factorial 
design 
Abbreviations: 
API, Active Pharmaceutical Ingredient 
CMAs, Critical Material Attributes 
CCS, Critical Control Strategy 
CPPs, Critical Process Parameters 
CQAs, Critical Quality Attributes  
DoE, Design of Experiments  
DS, Design Space 
ICH, International Council for Harmonisation  
LD, Laser diffraction  
MP-SA, Micro-sized lipid particle containing salicyclic acid  
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Nanostructured lipid carriers containing salicyclic acid (NLC SA) 
NSAID, Non-steroidal anti-inflammatory drug  
PAT, Process Analytical Technology  
QbD, Quality by Design  
QRM, Quality Risk Management  
QTPP, Quality Target Product Profile  
REM, Risk estimate matrix  
SA, Salicyclic acid  
 
1. Introduction 
Application of the „quality by design” methodology according to the ICH Q8 guideline is a 
fairly new approach in the development process of new pharmaceutical products. The QbD 
approach is usefull in the daily pharmaceutical industrial practice (ICH Q8, 2009).  It is a 
systematic approach that begins with predefined objectives, and emphasizes product and 
process understanding, as well as process control, based on sound science and quality risk 
management. The process starts with the determination of the quality target product profile 
(QTPP) and the critical quality attributes (CQAs). Critical material attributes (CMAs) and 
critical process parameters (CPPs) are identified, as well as risk assessment is carried out 
(ICH Q9, 2006) in order to identify the material attributes and process parameters which 
potentially affect product CQAs.  
Therefore, the QbD approach is more proactive and refers to a systematic process compared 
to the mainly empirical methodologies used earlier (Beg, S. et al., 2015, Shah, B. et al., 2015, 
Xu, X. et al., 2011 Xu, X. et al., 2012, Kan, S. et al., 2014, Wang, J. et al, 2015, Kovacs, A et 
al., 2016). Risk assessment and the Design of Experiments (DoE) techniques within the risk 
assessment process are key elements of QbD methodology (Fig.1). Risk assessment includes 
the identification of potential hazards plus the analysis and evaluation of the risks associated 
with the exposure to these hazards (Beg, S. et al., 2015). The ICH Q9 guideline lists several 
quality management tools (e.g. Ishikawa diagram, Pareto analysis, risk estimate matrix etc.) 
and favors the Design of Experiments (DoE) techniques (e.g. screening techniques, 
interaction effect techniques etc.) (Singh et al 2011).   
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Fig. 1. Flow chart of Quality by Design approach in formulation development  
 
Our hypothesis that the adaptation of the QbD based dosage form development in the early 
research phase leads to a more systematic R&D approach, and consequently gives a greater 
potential to the final product to reach the market earlier, has already been proved for newly 
developed nasal formulas (Pallagi, E. et al., 2015).  
Now the QbD approach is applied to the development of a complex dosage form, namely for 
Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLCs), which are potent 
drug delivery systems for e.g. dermal use. These systems are derived from o/w emulsions by 
replacing the lipophilic liquid phase with solid lipid(s), which are dispersed in an external 
aqueous phase with suitable emulsifier(s) (Baroli, B., 2010). The active substance is present in 
a dissolved or dispersed form, and is characterized by a size range of 40 to 1000 nm (Müller, 
R.H. et al., 2002, Pardeike, J., et al., 2009, Subedi, R.K., et al., 2009). Nanostructured Lipid 
Carriers (NLCs) is the term used for second generation solid lipid nanoparticles that contain a 
lipid matrix of mixed solid and liquid lipids.  
The main advantages of these systems include the following: (1) they are ideal carriers to 
incorporate low water-soluble active substances and to stabilize oxidation-/photo-sensitive 
materials (Müller, R.H. et al., 2002, Pardeike, J., et al., 2009); (2) as dermally applied systems 
(McGrath, J.A. and J. Uitto, J., 2010, Prow, T.W., et al., 2011,  Cevc, G. and Vierl, U., 2010) 
they ensure close contact with the lipid bilayer of the stratum corneum, resulting in a more 
efficient and deeper drug penetration into the skin layers (Yang, X., et al., 2013). Their 
occlusive properties resulting from film formation were also reported for NLC formulations 
(Wissing, S.A. and Müller, R.H., 2002a, Wissing, S.A. and Müller, R.H., 2002b), as well as 
their protective capacity against environmental effects such as UV radiation (also called 
physical UV filter function) (Müller, R.H. et al., 2014, Lacatusu, I., et al., 2011).  
Salicylic acid (SA) as an NSAID drug with antifungal, anti-infective and keratolytic 
properties was used as model drug because of its wide therapeutic use (e.g. for the treatment 
of acne, psoriasis, callouses, corns, keratosis pilaris and warts), its physicochemical properties 
(molecular weight <400 Da, log P = 2–3.8), and also because SA is poorly water soluble, 
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thereby it is a good candidate for our studies. Incorporating salicylic acid into NLC 
nanoparticles may protect against the irritating side effects and may enhance skin penetration, 
thereby it is possible to achieve the same effect with less amount of active substance 
compared to conventional pharmaceutical dosage forms (Casanova, F., 2015). 
The first aim of our present work was to adapt the QbD approach in the optimalization and 
development of stable salicyclic acid loaded nanostructured lipid carriers for dermal use. As 
the first step of this process, the QTPP and CQAs were determined, then an initial risk 
assessment was carried out to optimalize the material attributes (CMAs) and process 
parameters (CPPs) affecting the critical quality attributes (CQAs) of SA-containg NLC 
systems. Our further aim was the practical implementation of the 2
3
 factorial design method 
as a risk assessment tool in order to determine the optimal composition for the formulation. 
Thirdly, methods of monitoring selected critical parameters as “in-process” and as final 
product quality control measures were also adopted and recommended for the NLCs. 
 
2. Materials and Methods 
2.1. Materials 
Salicylic acid was purchased from Sigma-Aldrich (USA), Compritol 888 ATO (glyceryl 
behenate/dibehenate) was supplied by Azelis Hungary Ltd. (Hungary), Miglyol 812 
(caprylic/capric triglyceride) was provided by Sasol GmbH (Germany) and Cremophor RH 60 
(PEG-60 hydrogenated castor oil; HLB value:15-17) was kindly supplied by BASF SE 
Chemtrade GmbH (Germany). Bidistilled water was used throughout the experimental work. 
All other chemicals were of analytical grade unless otherwise stated. 
 
2.2 Methods 
2.2.1. Definition of the QTPP 
The initial step of the QbD based development is to define the target product profile (TPP) 
and the selected QTPP based on requirements of stakeholders (patient expectations, industrial 
and regulatory aspects). TPP includes the defintion of the route of administration, the dosage 
form, maximum and minimum doses, appearance etc. QTPPs are quality, safety and 
efficiency features of a product, such as stability, drug release profile, pharmacokinetical 
attributes, purity, bioavailability etc. depending on the specific dosage form, the route of 
administration and the therapeutic aim (ICH Q8, 2009).  
 
2.2.2. Determination of the CQAs 
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The secound step of the QbD based development is to define and summarize the quality 
attributes of a product which have to be ensured during development and production in order 
to achieve the required final quality. The CQAs are derived from the QTPP and are based on 
prior product knowledge. CQAs include the physical, chemical, biological, or microbiological 
properties that should be within an appropriate limit, range, or distribution to ensure the 
desired product quality (ICH Q8, 2009). CQAs are dependent on the raw materials on the in-
process materials used, as well as on the final drug product. The CQAs may include 
particle/droplet size, drug release, entrapment efficiency, purity, pH, viscosity etc. Regarding 
that the size range of the NLC system is between 10–1000 nm (“nano” range), particle size 
and particle size distribution are further risk parameters in the present case.  
 
2.2.3. Determination of the CMAs and CPPs 
The third step of the QbD based development is to determine the material attributes and 
process parameters (based on prior knowledge, literature data and previous laboratory 
experiments) that may influence product CQAs, and also to find the functional relationships 
between these material attributes and process parameters related to product CQAs (ICH Q8, 
2009). Factors of interest include properties of the API, properties of the excipients (e.g., lipid 
and surfactant), and process parameters (e.g. homogenization time and temperature).  
 
2.2.4. Initial risk assessment: screening design 
Risk assessment is the focus of the QbD based product development. Risk assessment consists 
of identification, analysis and evaluation of risks detected for a given formulation (ICH Q9, 
2006). In case of a dermally used NLC system, the following failure modes/risk factors may 
occur: inadequate particle size of the drug product (NLC preparation), inadequate drug 
substance solubilty, inadequate in vitro drug release rate or time, inhomogenity of the drug 
product, kinetic instability (e.g. aggregation, phase separation), and incompatibility between 
the drug substance and the excipients (Chang et al., 2013, EMA/CHMP, 2013). These risks 
are best evaluated by using an Ishikawa diagram. The risk estimate matrix allows the 
evaluation of the critical factors from a large number of parameters affecting the CQAs, 
allowing to reduce the number of risk factors be studied in the experimental phase. The Pareto 
chart shows the relationships between CMAs or CPPs and CQAs, respectively and it can be 
used to determine the most critical parameters to be controlled for be during the drug 
development process. Screening of parameters and defining the critical control points were 
carried out by the LeanQbD™ software (QbD Works LLC, Fremont, CA, USA) (Kovacs, A. 
et al., 2016, Pallagi, E. et al., 2015).  
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2.2.5. Preparation of the NLC formulation 
NLC formulations were prepared by ultrasonication method using an UP 200s Ultrasonic 
Processor (Hielscher Ultrasonics GmbH, Germany). Salicylic acid equaling to 4 w/w% was 
dissolved in the melted blend of solid lipid (Compritol ATO 888) and liquid lipid (Myglyol 
812) at 75 °C. Salicylic acid concentration was 0.4 w/w% in final formulations and total lipid 
concentration was 10 w/w% in each samples. The surfactant was dissolved in bidistilled water 
at the same temperature. The aqueous phase was added to the lipid phase and was stirred with 
Ultra Turrax T25 (IKA-Werke, Germany) for 60 seconds at 10,000 rpm. The pre-emulsion 
was subjected to ultrasonication at a continuous mode at 70% amplitude for 10 or 20 minutes. 
Blank NLC was prepared with the same procedure, but without adding the active agent. The 
reference micro-sized particle preparation (MP SA) was prepared using the same composition 
and the same procedure, but no ultrasonication. 
 
2.2.6. Preformulation study 
Analysis of the API in the NLC compositions with X-ray powder diffraction (XRPD) 
The XRPD analysis was performed with a Bruker D8 Advance diffractometer system (Bruker 
AXS GmbH, Karlsruhe, Germany) with Cu K λI radiation (λ = 1.5406 Å). The samples were 
scanned at 40 kV and 40 mA from 3 to 40 2θ, at a scanning speed of 0.1/s and a step size of 
0.010. Before the measurement, lipid mixtures and lipid-drug mixtures were melted and left to 
cool down to room temperature. The solid lipid was examined as received, without any 
treatment. 
 
2.2.7. Design of experiments using the 2
3
 factorial design 
In a factorial experiment (factorial design, FD) all levels (x) of a given factor (k) are 
combined with all levels of every other factor included in the experiment, and the total 
number of experiments are x
k 
(Singh et al., 2011). In this case the 2
3
 full factorial design was 
used to determine the optimal ingredient ratio and preparation settings for the SA loaded 
NLCs. The effects of the factors are examined at two levels (+1 and –1). The levels are 
chosen based on literature data and previous laboratory experiments (Table 1A).  For the 
experimental design process, eight different NLC samples (Table 1B) were prepared in 
triplicates according to the 2
3
 full factorial design methodology. Statistical data analysis was 
performed using StatSoft. Inc. Statistica for Windows 11. 
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Table 1. (A) Values of the examined independent variables (X1, X2 and X3) and types of 
dependent variables (Y1, Y2). (B)  Summarizes the compounds of the prepared formulations. 
A 
Type of variables Levels 
Independent variables Low (–1) High (+1) 
X1: surfactant concentration (w/w%) 1 5 
X2: solid/liquid lipid ration 7:3 9:1 
X3: ultrasonication time (min) 10 20 
 
Dependent variables   
Y1: particle size   
Y2: particle size distribution   
 
B 
 NLC 1 NLC 2 NLC 3 NLC 4 NLC 5 NLC 6 NLC 7 NLC 8 
Cremophor 
RH 60 (w/w%) 
 
1 1 5 5 1 1 5 5 
Lipid ratio 
 
9:1 7:3 9:1 7:3 9:1 7:3 9:1 7:3 
Ultrasonication 
time (min) 
 
10 10 10 10 20 20 20 20 
         
 
2.2.8. Characterization of NLC SA 
Particle size analyzis 
Determination of particles size and particle size distribution (span) were performed by laser 
diffraction (LD) using a Mastersizer 2000 (Malvern Instruments, UK). Three values, namely 
d(0.1), d(0.5), and d(0.9) were evaluated, indicating that 10%, 50%, and 90% of the analyzed 
particles are below a certain size (volume distribution). The span value describing the width 
of the particle size distribution curve ((d(0.9)-d(0.1))/d(0.5)) was also calculated. The 
measurement medium was purified water, with a refractive index of 1.33. The refractive index 
was set to 1.456.  
 
In vitro drug diffusion 
The in vitro drug diffusion analysis was performed by using the dialysis bag method (Araújo, 
J., et al., 2012, Kheradmandnia, S., et al., 2010). 200 µl of the NLC formulation was sealed in 
a Spectra/Por
®
 4 dialysis membrane with Spectra/Por
®
 Closures (Spectrum Laboratories Inc., 
Rancho Dominguez, CA, USA), and placed into 25 ml of phosphate-buffered saline (PBS) 
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(pH = 7.4). The system’s temperature was 32°C, and continuous stirring at 450 rpm was 
applied. After 0.5, 1, 2, 3, 4, 5 and 6 hours 1 ml samples of the bulk solution were taken. The 
withdrawn samples were replaced by 1 ml of PBS to maintain sink conditions. The samples 
were analyzed at 295 nm with a Unicam Evolution 201 UV/Vis spectrophotometer (Thermo 
Fisher Scientific Inc., Waltham, MA, USA). The reference preparation (MP SA) was 
subjected to the same procedure. 
 
2.2.9. Statistical analysis 
Results of the factorial design experiment were analyzed by the statistical software of 
Statistica for Windows software version 11. Statistical analysis of the in vitro data were 
carried out using the two-way analysis of variance test (Bonferoni’s posttest comparision) by 
the Prim for Windows 5 Software (GraphPad Software Inc. La Jolla, CA, USA). 
 
3. Results and discussion 
3.1. Definition of QTPP and CQAs for NLC SA for dermal use 
The first step of a QbD-based drug development process is defining the target product profile 
(TPP) and the selected QTPP. Using the QbD methodology, we aimed to develop and 
optimalize a stable NLC SA formula that has a reduced SA concentration but a non-inferior or 
an enhanced therapeutic effect during dermal use. QTPP for the NLC system include 
therapeutic effectiveness, stability and the dissolution profile of sustained drug release. 
Therapeutic effectiveness of an NLC SA for dermal use depends on the bioavailability and the 
solubility of API. Solubility of the API is one of the most critical parameters affecting 
whether the desired drug concentration within the stratum corneum is achieved. Stability is 
another important parameter to ensure the safety and efficacy of the drug product. Particle 
size and particle size distribution are expected to influence stability. The mean particle size 
(d0.5) and particle size distribution width (span) together are siutable parameters to check the 
stability of the nanoparticles. The aggregation of the particles are clearly indicated by these 
increasing values during the prepration process and as well as the long term stability. 
Furthermore, particle size and solubility of the API in the lipid matrix are expected to 
influence drug release, and consequently skin transport as well (Sütő et al., 2015b). Therefore, 
particle size and solubility of the API are idenitified as CQAs. Additionally, numerous 
interactions may appear between the parameters. Risk assessment can help to identify these 
interactions and their effects can be evaluated. Table 2 lists the QTPP parameters with their 
targets and their justification. 
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Table 2. Quality Target Product Profile (QTPP) of SA containing NLC. 
QTTP parameters Target Justification 
Dosage form NLC Salicylic acid is poorly water soluble 
and has skin irritative properties. 
Nanostructured lipid carriers (NLC) 
overcome these problems. The small 
size of the NLCs ensures close contact 
between the lipid particles and the lipid 
bilayer of the stratum corneum, 
resulting in an increased penetration of 
the drug into the deeper layers of the 
skin. 
 
Route of 
administration 
 
Dermal 
 
The advantage of dermal preparations 
is their local administration at the 
affected site, thereby avoiding systemic 
side effects appearing in case of oral 
administration.  
 
Therapeutic effect 
 
Anti-inflammatory 
 
Salicyclic acid is an NSAID with 
antifungal, anti-infective, keratolytical 
and anti-inflammatory properties. Its 
indications include e.g. hyperkeratotic 
skin disorders, acne, warts and calluses 
scalp conditions and fungal nail 
infections. 
 
Stability (physical, 
chemical, biological) 
No visible signs of aggregation 
at the time of preparation and 
within 1 months  afterwards (at 
room temperature) 
Stability is required in order to retain 
the therapeutic effect of the drug 
during shelf-life and is a crucial 
requirement for marketing 
authorization. 
 
Dissolution profile 
 
Sustained drug release 
 
Sustained drug release can reduce the 
irritation caused by SA. 
 
Dosage strenght 
 
0.4g/100g 
 
Usual adult dosage of SA in topical 
preparations for acne is 0,5 to 
2,0w/w% (FDA, 2011). From the lipid 
nanoparticle film applied to the skin,  
diffusion of drug molecules’ into skin 
layers is driven by the concentration 
gradient. Dermal penetration and 
therefore intradermal  drug 
concentration is enhanced by the 
occlusive effect of the topical film. As 
a result of that, a lower dosage strength 
can produce the required terapeutic 
effect. 
 
Container closure 
system 
 
Appropriate for the dosage form 
 
It is needed to ensure target shelf-life 
and the NLC’s safety and is a  
requirement for marketing 
authorization. 
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After determining the QTTP parameters, the next step is identifiing the quality attributes that 
have to be assured for the proper quality of the NLC SA product. The CQAs are derived from 
the QTPPs. The quality attributes identified include particle size, particle size distribution, 
aggregation, physical attributes of the drug product, dissolution rate (dissolution speed), 
dissolution efficiency (dissolution performance of the drug product), pH, solubility of the 
API, entrapment efficiency and viscosity. Table 3 illustrates the potential CQAs affecting the 
quality of the NLC SA formulations along with justification for each of them. 
 
Table 3. Quality Attributes and CQAs of SA-containing NLC  
Quality attributes Target Is it a 
CQA? 
Justification 
Physical 
attributes 
(colour, odour, 
appearance) 
Opalescent to white, odourless 
dispersion 
No Physical attributes are not critical, 
because they are not directly 
linked to efficiency and patient 
safety. 
 
Particle size 
 
Mean particle size range: 100–
200 nm 
 
Yes 
 
Smaller particle size allows easier 
penetration through the stratum 
corneum. It is considered as 
critical for the formula. 
 
Particle size 
distribution 
 
Span value ≤ 1 (the span value 
refers to the width of the 
particle size distribution.) 
 
Yes 
 
Low span values indicate the 
narrow particle size distribution. 
Based on the work of the research 
group (Sütő, B. et al., 2015a ) we 
defined as the target, the span 
value should be ≤1. It is 
important for the stability of the 
NLC. 
 
Dissolution rate  
 
Sustained  
 
Yes 
 
Required for a long-lasting 
dermal effect.  
 
Dissolution 
efficiency in 60 
min 
≥50 % and higher than MP Yes Dissolution performance is an 
indicator of drug release from the 
salicylic acid loaded NLC 
system. It is important for 
enhancing the therapeutic effect. 
A higher dissolution efficiency of 
the API results in enhanced 
therapeutic benefits. 
 
Aggregation d(0,9) range: 100 nm (0,1 µm) 
to 200 nm (0,2 µm) 
Yes The d(0.9) range shows during 
the cooling phase of production 
the particles preserved the 
separateness.. It is important for 
the stability of the NLC during 
the preparation process. 
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Solubility of the 
API in lipid 
matrix 
High (approx. 90%) Yes It is an indicator of the 
dissolution efficacy of salicylic 
acid in lipid matrix. It is 
important for enhancing 
therapeutical effectiveness (Patel, 
J.N. et al., 2012). 
 
Entrapment 
efficiency 
min. 95% Yes It is an indicator of higher drug 
loading (Sütő et al. 2015b). 
 
 
Viscosity of 
NLC dispersion 
Range: 100–500 mPas Yes Viscosity may affect drug release 
and stability of the NLC. 
  
pH pH value: 4-8 Yes pH can influence the loading 
during the preparition. 
 
3.2. Initial Risk Assessment 
Risk assessment refers to the quantitative or qualitative estimate of the risks related to the 
NLC containing salicyclic acid. Risk factors are ranked by risk analysis. An Ishikawa 
(fishbone) diagram was constructed to identify the effects of key material attributes and 
process parameters for the development of NLC containig salicylic acid (Fig. 2.). It illustrates 
the causes and sub-causes affecting the CQAs of the NLC system. 
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Fig. 2. Ishikawa diagram: cause-and-effect relationship between the material and process 
variables for the quality attributes of NLC SA 
 
 
Risk estimate matrix 
After identifíing the QTPPs and the CQAs, the following step is determining the critical 
material (drug substance, excipients) and process parameters. The selected parameters are 
shown in Fig.3A, while Fig.3B presents the risk estimate matrix (REM) of interdependence 
rating between the CQAs and QTTPs for NLC SA, by assigning low, medium and high values 
to each of them. The risk estimation matrix (REM) represents the potential risk(s) associated 
with each material attribute(s) and/or process parameter(s) that have a potential effect on the 
CQAs. For the probability rating a 1(low)-3(medium)-9(high) scale was used, considering all 
QTTP, CMA and CPP factors and their relationships to the CQAs. The following factors were 
found to influence product quality: particle size (14%), particle size distribution (14%), 
particle aggregation (14%), the drug’s dissolution profile (rate: 12%; efficiency: 12%), 
solubility of the API (9%), pH (10%) and entrapment efficiency (9%). Fig.3C illustrates the 
risk associated with CMAs and CPPs. Eight CMA and CPP parameters were screened to 
determine their influence on the CQAs during the preparation of NLC. Probability rating was 
done the same way as it was for the previous REM. The interdependence between the QTPPs 
and CQAs, just as between the CQAs and CMAs and CPPs, was structured, and evaluated one 
by one with a LeanQbD Software.  
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Fig. 3. Selected QTPPs, CMAs, CPPs and CQAs and their interdependence rating with risk 
estimation matrix (Lean-QbD Software): Low=low risk parameter; Medium=medium risk 
parameter; High= high risk parameter 
 
Based on the REM results, a Pareto chart (Fig. 4.) was generated showing the severity scores 
of CQAs that lead us to the following conclusions: particle size, partical size distribution and 
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aggregation were the CQAs with the highest severity score  (>300) suggesting that these are 
the most critical parameters influencing the quality of NLC SA. The next highest category of 
severity scores is 200–299, and include the following parameters: dissolution rate, dissolution 
efficiency, pH, solubility of the API and entrapment efficiency, suggesting that these 
parameters have medium influence on the final product’s quality. Viscosity and physical 
attributes (colour, odour, appearance) were characterized by severity scores below 200, 
thereby having a low impact on the quality of the drug product. In this study the severity score 
threshold was set to 200, and any risk factors with a severity score above 200 was considered 
as a potential risk factor that should be paid attention during the development of the NLC. 
Based on the results of the risk assessment the particle size, the particle size distribution and 
the aggregation were the high risk parameters, therefore these parameters have been 
investigated in the first step which are only examined in this paper. 
The most critical parameters will be the dependent variables of the 2
3
 factorial design 
experiment which is the next phase of the QbD-based drug development process.  
 
 
 
Fig. 4. Pareto analysis of the identified CQAs 
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The Pareto chart in Fig. 5 shows the relationships between the CMAs, the CPPs and the 
CQAs, respectively, illustrating the most critical parameters which have to be paid attention 
during the drug development process. Based on the results of the initial risk assessment, three 
factors, namely surfactant concentration, the solid lipid/liquid lipid ratio and ultrasonication 
time were found to be highly critical factors for CQAs and for QTPP. These factors were 
further analysed as independent variables with the 2
3
 factorial design in order to further 
optimalize drug formulation. This way both time and costs can be saved by omitting 
unneccessary experiments.  
 
 
 
 
Fig. 5. Pareto analysis of selected material and process parameters 
 
3.3. Preformulation studies: X-ray powder diffraction (XRPD) analysis of the 
components 
XRPD measurements were carried out to determine the crystal structure of salicylic acid in 
the solid lipid, in the solid lipid/liquid lipid mixture and in the NLC. Diffractograms of (1) the 
pure API, (2) Compritol 888 ATO as solid lipid, (3) the solid lipid/liquid lipid mixture, (4) the 
physical mixture of components of NLC, (5) blank NLC and (6) NLC SA are shown in Fig. 6. 
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The diffractogram of salicylic acid (1) confirms that the drug is in the crystalline state. 
Comparing the diffractograms of the pure solid lipid (2) and the lipid mixture (3), it is clearly 
visible that the crystallinity of Compritol 888 ATO decreases and its structure becomes less 
ordered after the addition of Miglyol 812. This predicts a good drug loading ability of the 
lipid matrix. On the diffractogram of the physical mixture (4) no peaks of the drug are visible, 
which means that salicylic acid is dissolved in the lipid mixture. Diffractograms of the blank- 
and drug-loaded NLC formulations (5, 6) show a decreased crystallinity of the lipid matrix. 
Peaks of the drug cannot be seen on the diffractogram of NLC SA, which indicates the 
dissolved state of the active agent in the final formulation. 
 
 
Fig. 6. Diffractograms of pure API (1), Compritol 888 ATO (2), lipid mixture of 7:3 ratio (3), 
physical mixture (4), blank NLC (5) and NLC SA (6). 
 
3.4. Experimental design  
3.4.1 The 2
3
 factorial design 
DoE (Design of Experiments) is a risk assessment tool to detect the possible interactions 
between the factors affecting the drug development process and thus the quality of the final 
product. It is an effective method for an objective interpretation and the, implemetation of the 
results, considering simultanous parameter changes. Three independent variables and two 
dependent variables were selected based on the initial risk assessment. The effect of the 
independent variables (X1 – surfactant concentration; X2 – solid lipid/liquid lipid ratio, and 
X3 – ultrasonication time) on quality attributes of NLC dependent variables (Y1 – mean 
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particle size (d0,5), and Y2 – particle size distribution (span) were investigated using the 23 
factorial design (Fig. 7.). 
 
 
 
Fig. 7. Selected parameters for the 2
3
 factorial design based on the initial risk assessment 
 
3.4.2. Particle size analyzis 
Particle size and particle size distribution of the prepared NLC system were measured by laser 
diffraction (LD). The mean particle size d(0.5) of the NLC systems varied from 0.116 µm to 
21.574. The span values varied from 0.874 to 5.646 (Table 4).  
 
Table 4. Values of the independent (X1, X2 and X3) and dependent factors (Y1 and Y2) 
examined 
Sample 
name 
Surfactant 
concentration 
% (w/w) 
Solid 
lipid/liquid 
lipid ratio  
Ultrasonication 
time 
(min) 
Particle size 
(µm) 
Particle size 
distribution 
(span) 
NLC 1 1(–1) 9:1(+1) 10(–1) 12.735 3.023 
NLC 2 1(–1) 7:3(–1) 10(–1) 7.669 5.279 
NLC 3 5(+1) 9:1(+1) 10(–1) 0.121 1.074 
NLC 4 5(+1) 7:3(–1) 10(–1) 0.118 1.034 
NLC 5 1(–1) 9:1(+1) 20(+1) 21.574 3.032 
NLC 6 1(–1) 7:3(–1) 20(+1) 14.954 5.646 
NLC 7 5(+1) 9:1(+1) 20(+1) 0.121 1.025 
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NLC 8 5(+1) 7:3(–1) 20(+1) 0.116 0.874 
 
 
Salicylic acid concentration was 0.4 w/w% and total lipid concentration was 10 w/w% in each 
samples. The nanometer range could be reached in formulations NLC 3, 4, 7 and 8. Span 
values of these four samples show a narrow particle size width (low span values indicate the 
narrow particle size distribution). Samples NLC1, 2, 5 and 6 aggregated or became semisolid 
shortly after production, and their particle size was in the micrometer range. For these 
samples, span values indicate a broad, polydisperse particle size distribution.  
 
3.4.3. Statistical analysis of data 
Based on the 8 samples, the graphical results of the statistical ananlysis for mean particle size 
(d(0.5)) and particle size distribution are shown in Fig. 8-9. The probability values (p-value) 
calculated by regression analysis are shown in Table 5. 
 
Table 5.  Results of the statistical analysis for mean particle size (d(0.5)) 
Factor Effect 
 
t(1) 
 
p 
 
Coefficient 
 
Standard  
Error 
Coefficient 
 
(1)X1 
 
–14.1140 –36.3763 0.017497 –7.05700 0.194000 
Mean/Intercept 
 
7.1760 36.9897 0.017207 7.17600 0.194000 
1 by 3 
 
–4.0315 –10.3905 0.061081 –2.01575 0.194000 
(3)X3 
 
4.0305 10.3879 0.061097 2.01525 0.194000 
(2)X2 
 
2.9235 7.5348 0.084000 1.46175 0.194000 
1 by 2 
 
–2.9195 –7.5245 0.084114 –1.45975 0.194000 
2 by 3 
 
0.3890 1.0026 0.499181 0.19450 0.194000 
 
It can be seen factor X1 (surfactant concentration) on its own, as well as the three examined 
independent factors combined (surfactant concentration (X1), solid lipid/liquid lipid ratio 
(X2) and sonification time (X3)) exert a significant effect (p < 0.05) on the mean particle size 
(d(0.5)) The coupled factors were also tested, but did not give a significant effect (Table 5) . 
The mathematical model is shown in the following equation (Eq (1)) with good correlation R
2 
= 0.9994. 
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Y1 = 7.17600 – 7.05700*X1 + 1.46175 X2 + 2.01525 X3 –1.45975 X12   Eq (1) 
– 2.01575 X13 + 0.19450 X23 
 
A positive sign indicates a synergistic effect on the dependent factor examined, whilst a 
negative sign represents an antagonistic effect. Factor X1 (surfactant concentration) was 
indirectly proportional to the mean particle size (d(0.5)). The influence of X2 and X3 factors 
on factor Y1 were not significant, while the negative sign of effect in case of factor X2 
indicates an indirectly proportional and the positive sign of effect in case of X3 predicts a 
directly propotional relationship. These results are in accordance with the response surface 
plot (Fig. 8-9) and the Pareto chart (Fig. 10). 
The slope of the diagram in Fig. 8A indicates that the smallest particle size is achieved at a 
surfactant concentration of 5 w/w%, while there is no difference between the 9:1 and 7:3 lipid 
ratios. Surfactant concentration is also significant in Fig. 8B, illustrating that the smallest 
particle sizes results from the highest surfactant concentration (5w/w%) and a higher 
ultrasonication time (20 min). Based on Fig. 8C a lower lipid ratio (7:3) and a shorter 
ultrasonication time (10 min) produces the smallest particle size  
The statistical analysis of the independent factors for particle size distribution (span) shows 
similar results for mean particle size (d(0.5)) as shown in Table 6 and Fig. 9-10. 
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Fig.8. Response surface (3D) plot of the effects of variables on mean partical size of prepared 
NLC SA. 
Table 6. Statistical analysis of particle size distribution (span). 
Factor Effect 
 
t(1) 
 
p 
 
Coefficient 
 
Standard  
Error 
Coefficient 
 
X1 
 
–3.24318 –27.6670 0.023000 –1.62159 0.058611 
Mean/Intercept 
 
2.62327 44.7573 0.014221 2.62327 0.058611 
1 by 2 
 
1.26546 10.7955 0.058803 0.63273 0.058611 
X2 
 
–1.16957 –9.9775 0.063593 –0.58479 0.058611 
1 by 3 
 
–0.14675 –1.2519 0.429076 –0.07338 0.058611 
2 by 3 
 
–0.06181 –0.5273 0.691071 –0.03091 0.058611 
X3 
 
0.04183 0.3568 0.781811 0.02091 0.058611 
 
The mathematical model is shown in the following equation (Eq (2)) with good correlation  
R
2 
= 0.99898. 
Y2 = 2.62327 – 1.62159 X1 –0.58479 X2 + 0.02091 X3 + 0.63273 X12   Eq (2) 
–0.07338 X13 –0.03091 X23 
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Fig.9.Response surface (3D) plot of the effects of variables on particle size distribution of the 
prepared NLC SA. 
 
As seen in Fig. 9A, the combination of the highest surfactant concentration (5 w/w%) and the 
lowest lipid ratio (7:3) gives the smallest particle size distribution. Based on Fig. 9B, a higher 
surfactant concentration (5 w/w%) and a higher ultrasonication time (20 minutes) gives the 
smallest particle size distribution. Fig. 9C shows that the smallest particle size distribution is 
available with a higher ultrasonication time (20 min) and a higher lipid ratio (9:1). However, 
the desired partical size (100–200 nm) is achieved after 10 minutes at the 7:3 lipid ratio, while 
another 20 minutes of ultrasonication only slightly reduces particle size. Consequently, 
chooing the 7:3 lipid ratio is recommended. The standardized effect of the independent 
variables and their interaction on the dependent variable was also evaluated by preparing a 
Pareto chart. As illustrated by the Pareto charts in Fig. 10, only those factors crossing the 
vertical line have a significant effect.  Accordingly, the surfactant concentration was found to 
have the highest and a significant effect for mean particle size and particle size distribution. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
23 
 
 
Fig.10. Pareto chart: (A) mean particles size and (B) partical size distribution. 
 
According to these results, the lowest particle size can be achieved with a surfactant 
concentration of 5%, a lipid ratio of 7:3 and 20 min sonification time. These parameters apply 
for the formulation ‘NLC 8’, which was selected for further investigations. After selecting the 
optimal formula on the basis of the 2
3
 factorial design using response surface methodology 
and Pareto charts, we validated the preparation method. The validation process included the 
reproduction of the optimal formulation (NLC 8), and its characteristics, including particle 
size and particle size distribution were analyzed. Fig. 11 shows the fault tree for the 
optimalized formula of NLC SA. 
 
Fig.11. Optimalized formula for NLC SA and the parameters investigated (n=2). 
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3.5. Characterization of the optimalized NLC SA 
3.5.1. Particle size analysis and validation of the preparation method 
The particle size analysis confirmed the experimental results for the mean particle size and the 
particle size distribution as shown in Fig. 11 and Fig. 12. We have also demonstrated that 
these mean partical size (d (0,5)) and partical size distribution (span) values are appropriate 
and they meet the particle size requirements for nanosystems NLC (100–200 nm) as defined 
in QTPP. The experimental results (114 nm) of the validation process are comparable to the 
predicted values (116 nm). Thus, the preparation method defined by the risk assessment was 
found to be appropriate.  
 
Fig.12.  Results of the particle size analysis for the optimalized formula of NLC SA 
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3.5.2. In vitro drug diffusion 
In vitro diffusion of salicylic acid through the artificial membrane was examined using the 
NLC composition and the micro-particle reference preparation containing salicylic acid (MP 
SA). The extent of in vitro diffusion was calculated as the mean cummulative amount diffused 
at each sampling time during a period of 6 h (Fig. 13). Presently, the in vitro diffusion study 
used an “in process control” method to check the difference between the microparticle and 
nanoparticale formulation. As seen in Fig. 13, the amount of API released from the NLC after 
6 h was significantly higher than that released from the reference preparation. Furthermore, 
48% of the API incorporated into the nanostructured lipid carriers (NLC) was found to be 
dissolved within 60 minutes, while the drug release was only 39% in case of MP SA reference 
product. These results confirm that the target NLC SA was a nanosized formula with 
sustained drug release as defined in the QTPP, characterized by a minimum of 50% 
dissolution efficiency at 60 minutes. These results further confirm that particle size highly 
influences drug release. 
 
 
 
Fig.13. Release profiles of salicyclic acid from the micro-particle and the NLC system 
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4. Conclusion 
The present paper describes a successfully optimalized formula of nanostructured lipid 
carriers containing salicyclic acid, prepared by applying the QbD concept on the development 
process. Based on the results of the initial risk assessment, preformulation studies and 
experimental design (DoE), the optimal composition for the salicylic acid-loaded NLC system 
was defined. Initial risk assessment was carried out to select the CMA and CPP parameters in 
order to identify factors affecting the CQAs. Based on the results of the initial risk 
assessment, three CQAs, namely particle size, particle size distribution and aggregation were 
found to be highly critical attributes for the NLC SA. Furthermore, five CQAs, such as the 
dissolution rate, dissolution efficiency, pH, solubility of the API and entrapment efficiency 
were found to be attributes of medium influence. The initial risk assessment also revealed that 
three factors, namely surfactant concentration, the solid lipid/liquid lipid ratio and 
ultrasonication time were highly critical factors for the CQAs. In order to assure the desired 
NLC SA quality, the individual effects of CMAs and CPPs on CQA were evaluated by the 2
3
 
factorial design. The most critical CMAs and CPPs were chosen to be the independent 
variables and the CQAs were chosen to be the dependent variables in the 2
3
 factorial design 
process.   The optimalized formula of NLC SA was found to be characterized by a surfactant 
concentration of 5%, a 7:3 lipid ratio and 20 min ultrasonification time. The above-mentioned 
risk assessment protocol (including the Ishikawa diagram, the risk estimate matrix and the 
Pareto chart as calculated by the LeanQbD Software), as well as the factorial design was used 
for each step of formula optimalization.  Future development of NLC SA systems would be 
greatly facilitated by an enhanced practical understanding of the behavior of these systems. 
The risk assessment method is a helpful tool for the optimal product development process, 
allowing to define the optimal NLC formulation. Based on these results, a promising salicylic 
acid-loaded NLC formulation could be developed which can function as a potential dermal 
drug delivery system in the treatment of acne, psoriasis and eczema.  
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